Figure 6.
Impact of a neutralizing anti-FPRL-1/ALX mAb on ANXA1 effects PMN interaction with HUVECs under flow. (A) PMNs were incubated with a neutralizing anti-FPRL-1/ALX mAb (6C7-3, 5 μg/mL) for 1 hour at 37°C prior to addition of 30 μM peptide Ac2-26. (B) PMNs were incubated with a neutralizing anti-FPRL-1/ALX mAb (6C7-3, 5 μg/mL) for 1 hour at 37°C prior to addition of ANXA1 (10 nM). (C) PMNs were incubated with Boc2 (10 μM) for 10 minutes prior to addition of Ac2-26 (30 μM). In all cases, the number of rolling or adherent PMNs was quantified off-line. Data are presented as mean ± SEM of 3 to 5 independent experiments. *P < .05 versus respective control group. #P < .05 versus appropriate ANXA1 or peptide Ac2-26 group.

Impact of a neutralizing anti-FPRL-1/ALX mAb on ANXA1 effects PMN interaction with HUVECs under flow. (A) PMNs were incubated with a neutralizing anti-FPRL-1/ALX mAb (6C7-3, 5 μg/mL) for 1 hour at 37°C prior to addition of 30 μM peptide Ac2-26. (B) PMNs were incubated with a neutralizing anti-FPRL-1/ALX mAb (6C7-3, 5 μg/mL) for 1 hour at 37°C prior to addition of ANXA1 (10 nM). (C) PMNs were incubated with Boc2 (10 μM) for 10 minutes prior to addition of Ac2-26 (30 μM). In all cases, the number of rolling or adherent PMNs was quantified off-line. Data are presented as mean ± SEM of 3 to 5 independent experiments. *P < .05 versus respective control group. #P < .05 versus appropriate ANXA1 or peptide Ac2-26 group.

Close Modal

or Create an Account

Close Modal
Close Modal